GH Research PLC (NASDAQ:GHRS) Receives $45.00 Consensus PT from Analysts

GH Research PLC (NASDAQ:GHRS) has received an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $45.00.

Several research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research report on Friday, July 17th. Zacks Research raised GH Research from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. New Street Research set a $65.00 target price on shares of GH Research in a research report on Monday, August 10th. Citizens Jmp cut their target price on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, May 15th. Finally, Cantor Fitzgerald upped their price target on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 7th.

GH Research Price Performance

Shares of GHRS opened at $28.68 on Friday. The firm has a fifty day moving average price of $26.99 and a 200 day moving average price of $21.02. The stock has a market cap of $1.97 billion, a PE ratio of -28.68 and a beta of 1.29. GH Research has a 1-year low of $11.83 and a 1-year high of $31.44.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. As a group, equities analysts expect that GH Research will post -1.2 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in GH Research in the 2nd quarter valued at $79,000. BNP Paribas Financial Markets lifted its stake in shares of GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after acquiring an additional 10,600 shares during the period. Osaic Holdings Inc. lifted its stake in shares of GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the period. UBS Group AG boosted its holdings in shares of GH Research by 11.5% in the third quarter. UBS Group AG now owns 511,464 shares of the company’s stock valued at $7,314,000 after acquiring an additional 52,882 shares in the last quarter. Finally, Lynx1 Capital Management LP boosted its holdings in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after acquiring an additional 1,854,238 shares in the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.